Radnostix (INIS) Stock Overview
Manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, sodium iodide I-131 drug product, and radiochemicals for clinical research and life sciences in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
INIS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Radnostix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.06 |
| 52 Week High | US$0.11 |
| 52 Week Low | US$0.035 |
| Beta | 0.92 |
| 1 Month Change | -10.45% |
| 3 Month Change | 0% |
| 1 Year Change | 71.43% |
| 3 Year Change | 76.47% |
| 5 Year Change | 18.93% |
| Change since IPO | -99.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| INIS | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 9.1% | 0.6% | -1.1% |
| 1Y | 71.4% | 2.2% | 14.7% |
Return vs Industry: INIS exceeded the US Life Sciences industry which returned 1% over the past year.
Return vs Market: INIS exceeded the US Market which returned 14.6% over the past year.
Price Volatility
| INIS volatility | |
|---|---|
| INIS Average Weekly Movement | 22.6% |
| Life Sciences Industry Average Movement | 8.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: INIS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: INIS's weekly volatility (23%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 42 | Shahe Bagerdjian | www.intisoid.com |
Radnostix, Inc. manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, sodium iodide I-131 drug product, and radiochemicals for clinical research and life sciences in the United States and internationally. It operates through five segments: Theranostics Products, Cobalt Products, Nuclear Medicine Standards, Medical Devices, and Fluorine Products. The Theranostics Products segment produces and distributes Iodine-131 generic drug product and various isotopically pure radiochemicals for medical, industrial, or research applications.
Radnostix, Inc. Fundamentals Summary
| INIS fundamental statistics | |
|---|---|
| Market cap | US$32.35m |
| Earnings (TTM) | -US$231.26k |
| Revenue (TTM) | US$14.07m |
Is INIS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INIS income statement (TTM) | |
|---|---|
| Revenue | US$14.07m |
| Cost of Revenue | US$5.64m |
| Gross Profit | US$8.43m |
| Other Expenses | US$8.66m |
| Earnings | -US$231.26k |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.00044 |
| Gross Margin | 59.89% |
| Net Profit Margin | -1.64% |
| Debt/Equity Ratio | 147.1% |
How did INIS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/02 11:24 |
| End of Day Share Price | 2026/01/02 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Radnostix, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mauro Suarez | Alliance Global Partners |
| David Matthew Kratochvil | Alliance Global Partners |